Abstract:Objective To investigate the gene mutation of epidermal growth factor receptor (EGFR) in the lung tissue and pleural fluid of the patients with advanced non-small cell lung cancer (NSCLC), so as to provide medical evidence for the selection of targeted therapy in those patients with lung cancer .Methods One hundred and eighteen patients confirmed to have advanced NSCLC through histology or cytology were chosen for the study .Gene mutation of EGFR ( exon 18-21 ) in the lung tissue and pleural effusion cell block obtained with different methods was detected by using amplification refractory mutation system ( ARMS) -qPCR.Results (1) Of the 118 patients with advanced NSCLC , 45 were detected to have EGFR gene mutation , with the mutation rate of 38.1%, in which male patients accounted for 44.4%and female patients accounted for 55.6%.(2)The rate of EGFR mutation varied with differ-ent ways of sample collection , with surgical excision and CT-guided lung biopsy having relatively higher detection rate and pleural effu-sion cell block having relatively lower detection rate .Statistical significance could be noted , when comparisons were made between them (P<0.05).(3)The positive rate of pleural fluid samples varied with the samples collected at different stages of the disease .With the progress of the disease, the positive rate tended to increase.However, no statistical significance could be seen, when comparisons were made between different stages (P>0.05).(4)In the patients with EGFR gene mutation , the patients with 19 exon deletion and 21 exon L858R mutation had relatively higher proportion , accounting for 40%and 42.2%respectively.The patients with 18 and 20 exon dele-tion had relatively lower proportion , accounting for 8.9%and 6.7%respectively.Statistical significance could be noticed , when com- <br> parisons were made between the former two exons and the latter two exons (P<0.05).There were another 2 patients with simultaneous mutation of 19 and 21, which accounted for 4.4%of all the patients, and there were 43 patients with single gene mutation , which ac-counted for 95.6%.Detection results revealed that there were no patients with multi-gene mutation.Conclusion The detection of EG-FR gene should be performed in all the patients with advanced NSCLC , in order to provide evidence for the proper selection of targeted molecular therapy .

Relationship between epidermal growth factor receptor gene mutation and the efficacy of gefitinib in the treatment of advanced nonsmall-cell lung cancer

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Relationship Between Mutations of Epidermal Growth Factor Receptor in the Plasma and Pleural Effusion and Responses to Gefitinib in Advanced Pretreated Non-Small Cell Lung Cancer

Effect of gene mutation of epidermal growth factor receptor on targeting therapy of advanced non-small cell lung cancer

Effect of Gene Mutations of Epidermal Growth Factor Receptor on the Maintenance Therapy of Advanced Non-Small Cell Lung Carcinoma

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Effect Of Egfr Mutations On Gefitinib In Advanced Previous Treated Non-Small-Cell Lung Cancer

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Relative Abundance of EGFR Mutations Predicts Benefit from Gefitinib Treatment for Advanced Non-Small-cell Lung Cancer.

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer

[Role of EGFR Mutation Status in Patients with Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiotherapy].

Clinical Efficiency of Gefitinib in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status

The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.

Research on the gene mutation of epidermal growth factor receptor in the patients with advanced non-small cell lung cancer

Detection Of' Epidermal Growth Factor Receptor Mutations In Plasma By Mutant-Enriched Pcr Assay For Prediction Of The Response To Gefitinib In Patients With Non-Small-Celi Lung Cancer

Impact of Smoking on the Clinical Efficacy of Gefitinib Combined with Radiotherapy after Chemotherapy Failure in the Patients with Stages III and IV Non-Small-cell Lung Cancer

Relationship Between Epidermal Growth Factor Receptor Gene Mutation and Copy Number in Chinese Patients with Non-Small Cell Lung Cancer

Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer